17:57 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Melior begins Phase IIb trial for Type II diabetes candidate MLR-1023

Melior Discovery Inc. (Exton, Pa.) spinout Melior Pharmaceuticals I Inc. began a Phase IIb trial of MLR-1023 to treat adults with Type II diabetes uncontrolled on metformin. The 12-week, double-blind trial will enroll 400 patients in...
18:14 , May 3, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Two morpholine-based inhibitors of the CREBBP bromodomain could be useful for probing the role of the enzyme in diseases associated with epigenetic modifications. Screening of isoxazole analogs that inhibited CREBBP inhibitors in in...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

MLR-1023: Phase IIa data

A double-blind, U.S. and South Korean Phase IIa trial in 130 Type II diabetics showed that oral MLR-1023 for 4 weeks met the primary endpoint of reducing post-prandial plasma glucose between days 1 and 29...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

MLR-1023: Phase IIa started

Melior began a double-blind, placebo-controlled, U.S. and South Korea Phase IIa trial to evaluate 100 and 200 mg oral MLR-1023 once or twice daily for 4 weeks in about 120 patients. Bukwang Pharmaceutical Co....
15:46 , Dec 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Estrogen receptor; LYN kinase (LYN); phosphoinisitide 3-kinase (PI3K)

Cancer INDICATION: Breast cancerStudies in mice and human samples suggest inhibiting LYN could help treat estrogen receptor-positive breast cancers resistant to anti-estrogen therapy. In biopsies from breast cancer patients treated with estrogen deprivation therapy and...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Melior, Bukwang deal

Melior received the first milestone payment under a 2013 deal granting Bukwang exclusive rights to commercialize MLR-1023 in 36 countries in the Asia-Pacific region. The payment was triggered after FDA accepted Melior’s protocol for...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Melior, Bukwang deal

Melior Discovery's spinout, Melior Pharmaceuticals I Inc. (Exton, Pa.), granted Bukwang exclusive rights to commercialize MLR-1023 in 36 countries in the Asia-Pacific region. Melior said the deal includes countries as far west as India,...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Melinta management update

Melinta Therapeutics Inc., New Haven, Conn.   Business: Infectious   Hired: Lyn Baranowski as SVP of corporate development and strategy, formerly VP of commercial development at Pearl Therapeutics Inc., which AstraZeneca plc acquired   ...
07:00 , Aug 12, 2013 |  BioCentury  |  Regulation

Rescripting PAH

If FDA approves Bayer AG's entire dose titration scheme for Adempas riociguat, the agency will be departing from its past decisions on PAH drugs, which have been determined by significant improvements on six-minute walk distance,...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Generex Oral-lyn: Phase III data

An open-label, Indian Phase III trial in 209 Type II diabetics inadequately controlled on oral anti-diabetic agents showed that Generex Oral-lyn significantly reduced HbA1c from baseline to week 6 vs. injected human insulin (0.48% vs....